全文获取类型
收费全文 | 298696篇 |
免费 | 17327篇 |
国内免费 | 421篇 |
专业分类
耳鼻咽喉 | 4247篇 |
儿科学 | 10335篇 |
妇产科学 | 10275篇 |
基础医学 | 45307篇 |
口腔科学 | 7699篇 |
临床医学 | 24355篇 |
内科学 | 56357篇 |
皮肤病学 | 6404篇 |
神经病学 | 21170篇 |
特种医学 | 11657篇 |
外国民族医学 | 43篇 |
外科学 | 46899篇 |
综合类 | 7779篇 |
现状与发展 | 1篇 |
一般理论 | 162篇 |
预防医学 | 20243篇 |
眼科学 | 6978篇 |
药学 | 21064篇 |
中国医学 | 803篇 |
肿瘤学 | 14666篇 |
出版年
2019年 | 2331篇 |
2018年 | 3725篇 |
2017年 | 2709篇 |
2016年 | 3133篇 |
2015年 | 3571篇 |
2014年 | 4694篇 |
2013年 | 7342篇 |
2012年 | 9290篇 |
2011年 | 9694篇 |
2010年 | 6245篇 |
2009年 | 5635篇 |
2008年 | 8803篇 |
2007年 | 9678篇 |
2006年 | 9471篇 |
2005年 | 9061篇 |
2004年 | 8729篇 |
2003年 | 8214篇 |
2002年 | 7813篇 |
2001年 | 13368篇 |
2000年 | 13685篇 |
1999年 | 11452篇 |
1998年 | 3039篇 |
1997年 | 2796篇 |
1996年 | 2642篇 |
1995年 | 2550篇 |
1994年 | 2349篇 |
1992年 | 8338篇 |
1991年 | 8471篇 |
1990年 | 8274篇 |
1989年 | 8089篇 |
1988年 | 7322篇 |
1987年 | 7077篇 |
1986年 | 6723篇 |
1985年 | 6524篇 |
1984年 | 4764篇 |
1983年 | 4124篇 |
1982年 | 2470篇 |
1979年 | 4433篇 |
1978年 | 3234篇 |
1977年 | 2737篇 |
1976年 | 2505篇 |
1975年 | 2838篇 |
1974年 | 3359篇 |
1973年 | 3369篇 |
1972年 | 3119篇 |
1971年 | 2951篇 |
1970年 | 2841篇 |
1969年 | 2589篇 |
1968年 | 2539篇 |
1967年 | 2381篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
The CCR5Delta32 allele is associated with reduced liver inflammation in hepatitis C virus infection.
O Wald O Pappo Z B Ari E Azzaria I D Wiess I Gafnovitch H Wald U Spengler E Galun A Peled 《European journal of immunogenetics》2004,31(6):249-252
CCR5Delta32 is a deletion mutation in the chemokine receptor CCR5. Liver inflammatory activity was found to be significantly reduced (P = 0.005) in Jewish Israeli patients infected with the hepatitis C virus (HCV) carrying the CCR5Delta32 allele. The CCR5Delta32 allele does not alter susceptibility to HCV infection; however, it may play a role in the progression and outcome of the disease. 相似文献
993.
N K Nakagawa F Donato-Júnior C S Kondo M King J O C Auler-Júnior P H N Saldiva G Lorenzi-Filho 《The European respiratory journal》2004,24(5):805-810
Furosemide is a potent diuretic that affects water transfer across the respiratory epithelium, which is closely related to the transepithelial potential difference (PD). Water is a critical factor that determines mucus transport; an important lung defence mechanism that removes particles and microorganisms from the respiratory system. The aim of the present study was to investigate the acute effects of furosemide and hypovolaemia on tracheal PD and mucus properties. A total of 36 male mixed-breed dogs were submitted to anaesthesia, mechanical ventilation and haemodynamic monitoring. They were randomly assigned to three groups consisting of: a control group, a furosemide (40 mg i.v.) + hypovolaemia group, and a furosemide (40 mg i.v.) + volume replacement group. Tracheal PD and mucus samples were collected at time 0, 1 and 2 h after intervention. Mucus properties were analysed by means of a magnetic microrheometer and in vitro mucociliary transportability on the frog palate. Compared to controls, furosemide decreased PD to intermediate values, and only significantly when associated with hypovolaemia (-13+/-5 and -8+/-2 mV, time 0 and 2 h, respectively). In addition to the direct effect of furosemide, these results indicate that hypovolaemia also affects ion transport in the tracheal membrane. Furosemide and hypovolemia have no acute effects on respiratory mucus properties. 相似文献
994.
995.
996.
A Krause G H G Sinnecker O Hiort B Thamm W Hoepffner 《Experimental and clinical endocrinology & diabetes》2004,112(5):236-240
The sex hormone-binding globulin (SHBG) androgen sensitivity test has been used as a simple method to assess androgen receptor function in vivo. After a short term oral administration of the anabolic-androgenic steroid stanozolol the mean nadir serum concentration of SHBG is used as a measure of androgen response. We performed this test in order to evaluate its applicability in 16 patients with intersexual genital status: eleven with 46,XY gonadal dysgenesis and three with true hermaphroditism (group I), and in two patients with androgen insensitivity syndrome (AIS, group II). Ten healthy adult volunteers served as controls. In the two patients with AIS (group II) we found a diminished decrease of serum SHBG to 80.1 % and 80.7 %, respectively, indicating slight residual androgen responsiveness. In eleven patients of group I who were not on hormone replacement therapy, a mean nadir level of 51.7 +/- 8.7 % was found. In the controls the mean nadir serum SHBG level was significantly higher (62.7 +/- 5.2 %), probably due to interference of endogenous androgens and contraceptive medication with the stanozolol-induced SHBG decrease. In three gonadectomised patients who were on hormone replacement therapy the initial SHBG concentration was increased (513.5 +/- 239.1 nmol/l); the mean nadir SHBG concentration of 45.6 +/- 9.8 % of the initial level indicates an increased sensitivity of the test in patients in whom the counteracting ovarian androgens are absent. Our findings confirm that under standard test conditions the SHBG androgen sensitivity test is a simple diagnostic tool for the detection of androgen receptor malfunction. 相似文献
997.
Purpose: To report clinically, anotomically and angiographically documented cystoid macular edema (CME) associated with the use of latanoprost in 2 uncomplicated pseudophakic eyes. Methods: Retrospective rewiev of 2 patients who had history of latanoprost use and uncomplicated cataract surgery, described 相似文献
998.
S Lu D D Parekh O Kuznetsova S A Green C A Tozzi T F Reiss 《The European respiratory journal》2006,28(4):772-780
Cholinergic antagonists have been used since the early 1900s as bronchodilators for chronic obstructive pulmonary disease (COPD). The present study investigated whether an oral muscarinic M3-selective anticholinergic agent (OrM3) would provide an improved therapeutic advantage compared with an inhaled anticholinergic agent in patients with COPD. A 6-week, multicentre, randomised, placebo- and active-controlled, parallel-group study was performed at 56 sites in the USA. In total, 412 male and female patients (aged 35-86 yrs) with a clinical history consistent with COPD were randomised to receive OrM3 0.5, 2, 3 or 4 mg orally once daily, ipratropium bromide 36 mug by inhalation four times daily or placebo. OrM3 demonstrated a significant dose-related improvement in serial forced expiratory volume in one second and a trend for dose-related improvement in patient-reported symptoms compared with placebo. However, at a dose that provided efficacy less than that of ipratropium, the incidence of dose-related, mechanism-based side-effects for OrM3 exceeded those observed for ipratropium. In patients with chronic obstructive pulmonary disease, the oral M3-selective agent did not offer a therapeutic advantage over inhaled ipratropium. These results do not support the hypothesis that high selectivity for muscarinic M3 receptors over airway neuronal M2 receptors will represent a more effective therapy than current inhaled anticholinergics in obstructive airway disease. 相似文献
999.
1000.